Equities

Omeros Corp

Omeros Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.19
  • Today's Change-0.07 / -1.64%
  • Shares traded519.54k
  • 1 Year change+199.29%
  • Beta1.4864
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments172195157
Total Receivables, Net3724282
Total Inventory------
Prepaid expenses8.586.308.22
Other current assets, total------
Total current assets218443248
Property, plant & equipment, net212330
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term139123140
Other long term assets------
Total assets378591419
LIABILITIES
Accounts payable7.715.9913
Accrued expenses363438
Notes payable/short-term debt000
Current portion long-term debt/capital leases9.15960.65
Other current liabilities, total------
Total current liabilities5313652
Total long term debt330346314
Total debt340442314
Deferred income tax------
Minority interest------
Other liabilities, total202230
Total liabilities403505395
SHAREHOLDERS EQUITY
Common stock0.610.630.63
Additional paid-in capital728721706
Retained earnings (accumulated deficit)(754)(636)(683)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(25)8624
Total liabilities & shareholders' equity378591419
Total common shares outstanding616363
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.